| 260 | 3 | 21 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：通过网络药理学的方法研究“三骨汤”治疗骨转移癌的作用机理。方法：利用TCMSP、TCMID和TCM Database@Taiwan数据库筛选药物主要有效成分，利用Swiss Target Prediction和TCMSP数据库检索“三骨汤”相关治疗靶点，通过DisGeNet和Drugbank检索骨转移癌疾病基因，并将药物作用靶点和疾病基因进行映射，通过Cytoscape3.8.1软件进行可视化并筛选出核心基因，对潜在治疗靶点进行GO和KEGG通路分析。结果：“三骨汤”的主要有效成分有29个，包含413个靶蛋白。骨转移癌的疾病靶点有773个，其中112个是“三骨汤”治疗骨转移癌的潜在靶点。通过GO和KEGG通路分析发现“三骨汤”治疗骨转移癌是通过TNF、ErbB、FoxO、PI3K-Akt、Toll样受体、NOD样受体、Rap1等信号通路发挥抗癌、抑制骨转移和免疫调节的作用机制。“三骨汤”治疗骨转移癌的关键基因为VEGFA、AKT1、IL6、TP53、MAPK3、SRC、EGFR和CASP3等。结论：本研究通过网络药理学构建多层次相互作用的“中药-化合物-靶点-通路”网络示意图发现“三骨汤”治疗骨转移癌的作用机理涉及多个靶点和通路，可能与抗癌、抑制骨转移、调节免疫等相关。
Abstract：Objective:To study the mechanism of "Sangu Decoction" in the treatment of bone metastatic carcinoma by network pharmacology. Methods:TCMSP,TCMID and TCM Database@Taiwan databases and literature search were used to screen the main effective components of drugs. Swiss Target and TCMSP databases were used to search the potential therapeutic targets of "Sangu Decoction". DisGeNet and Drugbank databases were used to search the genes of bone metastatic carcinoma. Drug action targets and disease genes were mapped. Cytoscape 3.8.1 software was used to visualize and screen out the core genes. GO and KEGG pathway analyses were performed on potential therapeutic targets.Results:There were 29 main active ingredients in "Sangu Decoction",which contained 413 target proteins. There are 773 disease targets of bone metastatic carcinoma,of which 112 are potential targets of "Sangu Decoction" for the treatment of bone metastatic carcinoma. Through GO and KEGG pathway analysis,it was found that "Sangu Decoction" exerted anti-cancer,inhibiting bone metastasis and immune regulation mechanism through TNF,ErbB,FoxO,PI3K-Akt,Toll-like Receptor,NOD-like Receptor,Rap1 and other signaling pathways in the treatment of bone metastatic carcinoma. The key genes of "Sangu Decoction" in treating bone metastatic carcinoma are VEGFA,AKT1,IL6,TP53,MAPK3,SRC,EGFR and CASP3 and so on.Conclusion:In this study,we constructed a a multi-level interaction "traditional Chinese medicine-compound-target-pathway" network through network pharmacology,and found that the mechanism of "Sangu Decoction" in the treatment of bone metastasis cancer involves multiple targets and pathways,which may be related to anti-cancer,inhibition of bone metastasis,regulation of immunity and so on.
1 Hernandez RK,Wade SW,Reich A,et al.Incidence of bone metastases in patients with solid tumors:analysis of oncology electronic medical records in the United States[J].BMC Cancer,2018,18(1):44.
2 Fornetti J,Welm AL,Stewart SA.Understanding the bone in cancer metastasis[J].J Bone Miner Res,2018,33(12):2099-2113.
3 Coleman R,Cameron D,Dodwell D,et al.Adjuvant zoledronic acid in patients with early breast cancer:final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial[J].Lancet Oncol,2014,15(9):997-1006.
4 Wilson C,Bell R,Hinsley S,et al.Adjuvant zoledronic acid reduces fractures in breast cancer patients:An AZURE(BIG 01/04) study[J].Eur J Cancer,2018,94:70-78.
5 Stopeck AT,Lipton A,Body JJ,et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized,double-blind study[J].J Clin Oncol,2010,28(35):5132-5139.
6 Saad F,Gleason DM,Murray R,et al.Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer[J].J Natl Cancer Inst,2004,96(11):879-882.
7 Saad F,Gleason DM,Murray R,et al.A randomized,placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J].JNatl Cancer Inst,2002,94(19):1458-1468.
8 Fizazi K,Carducci M,Smith M,et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:A randomised,double-blind study[J].Lancet,2011,377(9768):813-822.
9 Wirth M,Tammela T,Cicalese V,et al.Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid:Efficacy and safety results of the Zometa European Study (ZEUS)[J].Eur Urol,2015,67(3):482-491.
10 W.L.Hsiao,L.Liu.The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights[J].Planta Medica,2010,76:1118-1131.
11 Y.W.Lee,T.L.Chen,Y.R.Shih,et al.Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer:A population-based study[J].Cancer,2014,120:1338-1344.
12孙霃平，刘胜.乳腺癌骨转移的中医文献溯源[A].中华中医药学会.第十二次全国中医、中西医结合乳房病学术会议论文集[C].中华中医药学会，2011:4.
13郭骏骐，郭卉艳，李兵.名老中医石玉林治疗乳腺癌骨转移30例[J].吉林中医药，1998,(2):3-5.
14王胜飞，王芹，付艳丽，等.中医药联合双磷酸盐治疗恶性肿瘤骨转移疗效的meta分析[A].中国中西医结合学会肿瘤专业委员会青年工作委员会、中国抗癌协会传统医学委员会青年工作委员会.第一届青年中西医结合肿瘤学术论坛论文集[C].中国中西医结合学会肿瘤专业委员会青年工作委员会、中国抗癌协会传统医学委员会青年工作委员会：中国中西医结合学会，2015:15.
15 Ara T,Declerck YA.Interleukin-6 in bone metastasis and cancer progression[J].Eur J Cancer (Oxford),2010,46(7):1223-1231.
16 Sosnoski DM,Krishnan V,Kraemer WJ,et al.Changes in cytokines of the bone microenvironment during breast Cancer metastasis[J].Int J Breast Cancer,2012,2012:160265.
17李志明，胡凯文，范毅南，等.补肾化痰法治疗骨转移癌疗效及安全性的Meta分析[J].中医学报，2020,35(6):1350-1356.
18李奥博.中西医结合治疗乳腺癌骨转移的临床研究[D].北京中医药大学，2016.
19 Chang JH,Lai SL,Chen WS,et al.Quercetin suppresses the metastatic ability of lung cancer through inhibiting Snail-dependent Akt activation and Snail-independent ADAM9 expression pathways[J].Biochim Biophys Acta Mol Cell Res,2017,1 864(10):1746-1758.
20 Chen HJ,Lin CM,Lee CY,et al.Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells[J].Oncol Rep,2013,30(2):925-932.
21 Shi ML,Chen YF,Liao HF.Effect of luteolin on apoptosis and vascular endothelial growth factor in human choroidal melanoma cells[J].Int Ophthalmol,2021,14(2):186-193.
22 Ha Duong JH,Blavier L,Baniwal SK,et al.Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis[J].Int J Cancer,2015,137(4):797-809.
23 Downward J.Mechanisms and consequences of activation of protein kinase B/Akt[J].Curr Opin Cell Biol,1998,10:262-267.
24 Cantley LC,Neel BG.New insights into tumor suppression:PTEN suppresses tumor formation by restraining the PI3K/Akt pathway[J].Proceed Nation Academy Sci,1999,96:4240-4245.
25 Hay N,Sonenberg.N.Upstream and downstream of m TOR[J].Genes Develop,2004,18:1926-1945.
26 Zhu W,Hu X,Xu J,et al.Effect of PI3K/Akt signaling pathway on the process of prostate cancer metastasis to bone[J].Cell Biochem Biophys,2015,72(1):171-177.
27 Li P,Shan JX,Chen XH,et al.Epigenetic silencing of micro RNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment[J].Cell Res,2015,25:1138-1148.
28 Osuala KO,Sameni M,Shah S,et al.IL-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration[J].BMC Cancer,2015,15:584.
29邓博，贾立群，高福云，等.三骨汤对骨转移癌OPG和RANKL表达的调节作用[J].中华中医药杂志，2010,25(9):1390-1392.
30 Li M,Ren CX,Zhang JM,et al.The effects of mi R-195-5p/MMP14 on proliferation and invasion of cervical carcinoma cells through TNF signaling pathway based on bioinformatics analysis of microarray profiling[J].Cell Physiol Biochem,2018,50(4):1398-1413.
31 Dong W,Cao Z,Pang Y,et al.CARF,As an oncogene,promotes colorectal cancer stemness by activating ERBB signaling pathway[J].Onco Targets Ther,2019,12:9041-9051．
32 Farhan M,Wang H,Gaur U,et al.FOXO Signaling pathways as therapeutic targets in cancer[J].Int J Biol Sci,2017,13(7):815-827.
33 Brunet A,Bonni A,Zigmond MJ.et al.Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor[J].Cell,1999,96 (6):857-868.
34 Shaw RJ,Cantley LC.Ras,PI(3)K and m TOR signaling controls tumour cell growth[J].Nature,2006,441(7092):424-430.
35 Weidinger C,Krause K,Mueller K,et al.,FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide[J].J Clin Endocrinol Metab,2011,96(9):E1361-E1371.
基本信息:
DOI：10.13210/j.cnki.jhmu.20210310.002
中图分类号:R285
引用信息:
[1]杨梦霞,毛昀,何理玉,等.“三骨汤”治疗骨转移癌作用机制探讨[J].海南医学院学报,2022,28(08):610-616.DOI:10.13210/j.cnki.jhmu.20210310.002.
基金信息:
国家自然科学基金面上项目（81973640）~~
2021-03-10
2021-03-10
2021-03-10